CoChat
Sign Up
Cited by 27Growth Hormone and Insulin-like Growth FactorsPituitary Gland Disorders and TreatmentsHormonal and reproductive studies

Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be?

Molitch, Mark E.·2002·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem.87.2.8339
Open this paper in CoChat — free account

Abstract

The availability of recombinant human GH has made it possible to treat not only children with impaired growth due to GH deficiency (GHD) but also adults with GHD. Information from a large number of studies has resulted in the description of a GHD syndrome in adults, and many studies have shown that several aspects of this syndrome can be reversed with GH treatment (for reviews see Refs. 1–5). However, in many subjects, the benefits cannot be clearly quantitated and the treatment remains quite costly. The average retail price for GH is about $40 per milligram at present. Average maintenance doses (based on achieving an IGF-I near the age-adjusted normal mean) for men and for women who are not receiving estrogen or who are receiving transdermal estrogen are about 0.3–0.4 mg/d, and for women receiving oral estrogen the dose is about double that (6–8). The maximum dose used usually does not exceed 1 mg/d (9). Thus, the yearly cost for GH therapy ranges from about $4,400 to about $14,600 for the GH plus any costs for syringes, etc.

Integrity signals

Registry

Crossref · 10.1210/jcem.87.2.8339

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Molitch, M. E.
Affiliations
Northwestern University (US)
Corresponding author
Molitch, Mark E.
ORCID
Molitch, Mark E.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2002-02-01
Volume
87
Issue
2
Pages
473-476
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem.87.2.8339
OpenAlex
W2094813885
Cited by
27
References
4
Citations by year
2013: 1
FWCI
2.71
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
adult growth hormone deficiency, diagnosis, diagnostic criteria, recombinant human growth hormone therapy, insulin-like growth factor I, treatment costs, hypopituitarism
MeSH terms
Adult, Endocrine System Diseases, Humans, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review